Tetrasubstituted cyclohexyl compounds as kinase inhibitors

A compound of Formula (I):

• wherein:
• groups attached to the cyclohexyl ring that are depicted inside the ring are all syn to each other, and all groups attached to the cyclohexyl ring that are depicted outside the cyclohexyl ring are syn to one another;
• R1a and R3a are selected from hydroxyl, C1-C4 alkyl, —(CH2)1-3Z, C1-C4 haloalkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 hydroxyalkyl, and amino,
• R2a is selected from C1-C4 alkyl, —(CH2)1-3Z, C1-C4 haloalkyl, and C1-C4 hydroxyalkyl,
• wherein Z is —OH, NH2, —NHC(O)Q, or —OC(O)Q, where Q is H or C1-C4 alkyl optionally substituted with one or more halo, OH, NH2, OMe, or CN;
• R2b is OH;
• ring A is a 5 or 6 membered aromatic ring selected from pyridinyl, pyrimidinyl, pyrazinyl, and thiazolyl and having N positioned as shown in Formula (I);
• Ring A is optionally substituted with 1 or 2 groups selected from halo, CN, NH2, hydroxy, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, and C1-C4 haloalkoxy;
• Ar is an aromatic ring selected from phenyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, thiazolyl, and pyrazolyl, or a 3-6 membered cycloalkyl or cycloalkenyl, each of which is optionally fused to an additional C5-6 cycloalkyl, C5-6 heterocyclyl, C5-6 heteroaryl or phenyl;
• and
• Ar is optionally substituted with up to three groups independently selected from halo, CN, NH2, hydroxy, C1-C4 haloalkyl, —S(O)p-Q2, C1-C4 haloalkoxy, —(CH2)0-3—OQ2, —O—(CH2)1-3—OQ2, COOQ2, C(O)Q2, —(CR′2)1-3—OR′ or —(CR′2)1-3—OR′ where each R′ is independently H or Me or C2-4 alkyl, and an optionally substituted member selected from the group consisting of C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, C1-6 alkylsulfonyl, C3-7 cycloalkyl, C5-7 cycloalkenyl, C3-7 heterocycloalkyl, C4-6 cyclic ether, C5-10 heteroaryl, and C6-10 aryl, each of which is optionally substituted with up to two groups selected from halo, CN, NH2, hydroxy, oxo, C1-4haloalkyl, C1-4 alkoxy, and Q2;
• where Q2 is H or a 4-7 membered cyclic ether, phenyl, C5-6 heteroaryl, or C1-6 alkyl, each of which is optionally substituted with one or more halo, oxo, OH, NH2, COOH, COOMe, COOEt, COONH2, COONHMe, COONMe2, OMe, OEt, or CN,
• and p is 0-2;
• or a pharmaceutically acceptable salt thereof.